123Genetix Inc.

123Genetix Inc. is a technology company that provides stem cell-based drug discovery and consulting services. Central to its operations is DeepNEU, an artificial intelligence-driven systems biology platform designed to create complex, editable computer models of disease biology. By simulating artificial human stem cells and organoids, the company enables researchers to perform virtual drug trials, generate new hypotheses, and conduct rapid prototyping of genetic modifications. The platform acts as a virtual laboratory environment, functioning similarly to a text editor for genes, which allows for the simulation of enzymes like CRISPR-Cas9 to assess efficacy and minimize off-target outcomes.

The platform is designed to empower medical researchers, particularly those focused on rare diseases, by providing tools for biomarker identification, experimental planning, and big data analytics. By facilitating individualized computer models, 123Genetix assists investigators in optimizing research strategies, improving grant proposals, and identifying potential therapeutic targets. The company's work aims to address the challenges of resource limitations and the complexity of rare disease research, offering a scalable computational approach to drug discovery that seeks to improve outcomes for patients and their families by accelerating the translation of research into effective treatments.